Patents for A61P 35 - Antineoplastic agents (221,099)
02/2001
02/15/2001CA2380312A1 Formulations for parenteral use of estramustine phosphate and albumin
02/15/2001CA2379977A1 Novel integrin receptor antagonists
02/15/2001CA2379608A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods
02/15/2001CA2378646A1 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
02/15/2001CA2378608A1 Compositions and methods related to claudin-7
02/15/2001CA2378480A1 Pharmaceutical compositions containing tripeptides
02/15/2001CA2378445A1 Use of anti-muscarinic agents for treating skin disorders
02/15/2001CA2378401A1 Implantable active ingredient depot
02/15/2001CA2378310A1 Arylsulfonamido-substituted hydroxamic acid derivatives
02/15/2001CA2378292A1 A knockout mouse for the tumor suppressor gene anx7
02/15/2001CA2378241A1 Benzanilides as potassium channel openers
02/14/2001EP1076091A1 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
02/14/2001EP1075840A2 Therapeutic and prophylactic uses of antithrombin III
02/14/2001EP1075531A1 Genomic sequences upstream of the coding region of the ifn-alpha2 gene for protein production and delivery
02/14/2001EP1075529A1 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
02/14/2001EP1075528A1 Endothelin-converting-enzyme like protein
02/14/2001EP1075519A2 Inhibitors of nf-kb activation
02/14/2001EP1075518A2 Human transcriptional regulator molecules
02/14/2001EP1075494A2 Compounds and methods for modulating nonclassical cadherin-mediated functions
02/14/2001EP1075493A2 Dna encoding snorf25 receptor
02/14/2001EP1075489A2 Water-soluble pro-drugs of 2,6-diisopropylphenol analogues
02/14/2001EP1075484A1 Novel anthracycline derivatives and their preparation
02/14/2001EP1075281A2 Polyol-ifn-beta conjugates
02/14/2001EP1075277A2 Methods for detecting and inhibiting angiogenesis
02/14/2001EP1075273A2 Inhibiton of helicobacter pylori proliferation
02/14/2001EP1075255A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof
02/14/2001EP1075184A1 Compositions and methods for active vaccination
02/14/2001EP0844874A4 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS
02/14/2001EP0815120B1 17-difluoromethylene-oestratrienes
02/14/2001EP0738280B1 Superactive vip antagonists
02/14/2001CN1284134A Methods of producing anti-angiogenic proteins: endostation, angiostation or restin, using pichia yeast expression system
02/14/2001CN1284130A Mutants of endostation, 'EM1' having ant-angiogenic activety and methods of use thereof
02/14/2001CN1284086A Conjugates useful in treatment of prostate cancer
02/14/2001CN1283994A Methods for treatment of neuro-and nephro-disorders and therapeutic toxicities using aminothiol compounds
02/14/2001CN1283633A Carboxynethylated derivative of ganoderic alpha-(1-3)-D-glucosan and its usage and preparing process
02/14/2001CN1283632A Ganoderic alpha-(1-3)-D-glucosan sulfate derivative and its usage and preparing process
02/14/2001CN1283629A Antineoplastic gancoderma mycelium-glucoprotein composition and its application and preparing process
02/14/2001CN1283628A Extract of shark cartilage and its preparing process
02/14/2001CN1283622A 6-hydroxy-3(4-[2-(piperidine-1-group)oxyethyl group]phenoxy)-2-(4-methoxy phenyl) benzo[b] thiophene hydrochloride salt
02/14/2001CN1283499A Aseptic 'Shenmai' powder for injection and its preparing process
02/14/2001CN1283483A Anticancer capsule 'Wushensu' and its extracting and preparing process
02/14/2001CN1283470A Liquid medicine for treating leukemia
02/14/2001CN1283464A High-molecular medicine resisting tumor metastasis and its preparing process
02/14/2001CN1283419A 'Wuzhi' health-care beverage
02/14/2001CN1061892C Oral liquid for treating tumor and its prepn method
02/14/2001CN1061867C Water preparation for eliminating tumor
02/13/2001US6187910 Chelation compounds, radionuclide metal chelate compounds and radiolabeled targeting moieties formed therefrom, and methods of making and using these compounds, complexes and conjugates for diagnostic and therapeutic use
02/13/2001US6187819 Protein kinase C activators and their use in decreasing expression of cell antigens
02/13/2001US6187814 By topically an farnesoid x-activated receptor (fxr) activator selected from farnesal, alkyl farnesyl ether, alkyl farnesoate, and 7-methyl-9-(3,3-dimethyloxiranyl)-3-methyl-2,6-nonadienoic acid, alkyl ester
02/13/2001US6187787 Bis(9-aminoacridine) DNA intercalating agents having antitumor activity
02/13/2001US6187786 Antitumor and anticarcinogenic agents
02/13/2001US6187783 Antitumor agents
02/13/2001US6187777 Pyrrolo(3,2-d)pyrimidine derivatives; neuropeptide y and corticotropin releasing factor modulators; dietetics; antidiabetic, antiinflammatory, and antitumor agents
02/13/2001US6187775 Acridone-derived compounds useful as antineoplastic and antiretroviral agents
02/13/2001US6187758 Anthracycline glycosides
02/13/2001US6187587 Nucleotide sequences; for diagnosis and treatment of related disorders
02/13/2001US6187568 Culture product of actinoplane; immunosuppressant, fungicides, antitumor agents
02/13/2001US6187562 Polynucleotides encoding human sphingosine Lyase
02/13/2001US6187312 Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of infectious diseases
02/13/2001US6187307 Cancer immunotherapy with semi-allogeneic cells
02/13/2001US6187306 Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
02/13/2001US6187287 Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
02/13/2001CA2315588A1 Use of antithrombin iii for the prophylaxis and therapy of diseases
02/13/2001CA2170065C Amide-derived bi-aromatic compounds; pharmaceutical and cosmetic compositions containing the same and their uses
02/13/2001CA2106176C Neutral lipids from kernel of job's tears
02/13/2001CA2016505C Water soluble high molecular polymerized drug preparation
02/13/2001CA2004202C Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
02/08/2001WO2001055118A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
02/08/2001WO2001009612A1 Modulating binding site on potassium channels used for screening
02/08/2001WO2001009390A1 Tenascin-c nucleic acid ligands
02/08/2001WO2001009361A1 Recombinant hsv-1 and live viral vaccines
02/08/2001WO2001009349A1 Gene encoding novel serine protease-like protein
02/08/2001WO2001009325A2 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations
02/08/2001WO2001009323A1 Guanosine triphosphate binding protein-coupled receptors, genes thereof and production and use of the same
02/08/2001WO2001009322A1 Guanosine triphosphate-binding protein coupled receptors, genes thereof and production and use of the same
02/08/2001WO2001009321A1 Gene encoding novel tsp1-like protein
02/08/2001WO2001009311A2 Methods of inhibiting cancer cells with adnf iii antisense oligonucleotides
02/08/2001WO2001009297A1 A method for selective electrofusion of at least two fusion partners having cell-like membranes
02/08/2001WO2001009293A2 Mammalian adhesion protease peptides
02/08/2001WO2001009192A1 Human monoclonal antibodies to prostate specific membrane antigen
02/08/2001WO2001009189A2 Compositions and methods for the treatment of tumors
02/08/2001WO2001009187A2 Human monoclonal antibodies to her2/neu
02/08/2001WO2001009186A2 Therapeutic compounds comprised of anti-fc receptor binding agents
02/08/2001WO2001009184A1 Human g-protein coupled receptor
02/08/2001WO2001009183A2 Polymorphisms in the human mdr-1 gene and applications thereof
02/08/2001WO2001009178A2 Human chaperone proteins
02/08/2001WO2001009170A1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app)
02/08/2001WO2001009169A2 Cysteine protease inhibitors
02/08/2001WO2001009159A1 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins
02/08/2001WO2001009156A1 HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS
02/08/2001WO2001009149A1 Bisplatinum complexes active through the oral route
02/08/2001WO2001009146A1 Radiolabelled bisphosphonates and method
02/08/2001WO2001009139A1 Aromatic esters of camptothecins and methods to treat cancers
02/08/2001WO2001009136A1 1,2-dihydro-1-oxo-pyrazino[1,2-a]indole derivatives
02/08/2001WO2001009133A1 NEW CYTOTOXIC PYRIDO[2,3,4-kl]ACRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
02/08/2001WO2001009129A2 1h-pirido[3, 4-b]indol-1-one derivatives
02/08/2001WO2001009128A1 Thiourea and isothiourea derivatives for inhibiting ras-transformed cell growth
02/08/2001WO2001009127A1 Benzoxazine derivatives and their therapeutic use
02/08/2001WO2001009125A1 Novel 8-carbonyl chroman derivatives, preparation and therapeutic use thereof
02/08/2001WO2001009124A1 8-carbonyl chroman derivatives, preparation and therapic use thereof